[go: up one dir, main page]

BR9911068A - Terapia combinada para tratamento de distúrbios bipolares - Google Patents

Terapia combinada para tratamento de distúrbios bipolares

Info

Publication number
BR9911068A
BR9911068A BR9911068-7A BR9911068A BR9911068A BR 9911068 A BR9911068 A BR 9911068A BR 9911068 A BR9911068 A BR 9911068A BR 9911068 A BR9911068 A BR 9911068A
Authority
BR
Brazil
Prior art keywords
treatment
bipolar disorders
combination therapy
bipolar
depression
Prior art date
Application number
BR9911068-7A
Other languages
English (en)
Inventor
Gary Dennis Tollefson
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BR9911068A publication Critical patent/BR9911068A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Electrotherapy Devices (AREA)

Abstract

Patente de Invenção: <B>"TERAPIA COMBINADA PARA TRATAMENTO DE DISTúRBIOS BIPOLARES"<D>. A presente invenção propicia métodos e composições para o tratamento de Distúrbio Bipolar, Depressão Bipolar ou Depressão Unipolar, todas essas com ou sem características psicóticas. Este método emprega um composto dotado de atividade como um antipsicótico atípico e um inibidor da reabsorção de serotonina.
BR9911068-7A 1998-05-29 1999-05-21 Terapia combinada para tratamento de distúrbios bipolares BR9911068A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8712698P 1998-05-29 1998-05-29
PCT/US1999/011314 WO1999062522A1 (en) 1998-05-29 1999-05-21 Combination therapy for treatment of bipolar disorders

Publications (1)

Publication Number Publication Date
BR9911068A true BR9911068A (pt) 2001-02-06

Family

ID=22203275

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9911068-7A BR9911068A (pt) 1998-05-29 1999-05-21 Terapia combinada para tratamento de distúrbios bipolares

Country Status (19)

Country Link
EP (1) EP0966967A3 (pt)
JP (1) JP2002516864A (pt)
KR (1) KR20010043731A (pt)
CN (1) CN1302207A (pt)
AU (1) AU756468B2 (pt)
BR (1) BR9911068A (pt)
CA (1) CA2332408A1 (pt)
CZ (1) CZ20004280A3 (pt)
EA (1) EA003611B1 (pt)
HR (1) HRP20000798A2 (pt)
HU (1) HUP0102511A2 (pt)
IL (1) IL139591A0 (pt)
NO (1) NO20005884L (pt)
NZ (1) NZ507981A (pt)
PL (1) PL344304A1 (pt)
SK (1) SK17492000A3 (pt)
TR (1) TR200003525T2 (pt)
WO (1) WO1999062522A1 (pt)
ZA (1) ZA200006817B (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6960577B2 (en) 1998-05-22 2005-11-01 Eli Lilly And Company Combination therapy for treatment of refractory depression
WO2000030648A1 (en) * 1998-11-23 2000-06-02 Sepracor Inc. 2-hydroxymethylolanzapine compositions and methods
UA77650C2 (en) * 1999-12-06 2007-01-15 Lundbeck & Co As H Use of serotonin reuptake inhibitor in combination with deramcyclane
FR2802101B1 (fr) * 1999-12-10 2003-02-28 Aventis Pharma Sa Association de cymemazine et d'un neuroleptique atypique
US6627653B2 (en) 2000-08-02 2003-09-30 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful for the treatment of depression
NZ526801A (en) * 2001-01-02 2005-07-29 Upjohn Co Norepinephrine reuptake inhibitor i.e. reboxetine and neuroleptic to treat disorders of the central nervous system
EP1404342A1 (en) * 2001-04-26 2004-04-07 Ortho-Mcneil Pharmaceutical, Inc. Treatment of psychotic disorders comprising co-therapy with anticonvulsant derivatives and atypical antipsychotics
AU2003268026A1 (en) 2002-07-30 2004-02-16 Peter Migaly Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions
WO2004047727A2 (en) 2002-11-01 2004-06-10 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for diagnosing and treating mood disorders
KR100858852B1 (ko) 2002-12-27 2008-09-17 오쓰까 세이야꾸 가부시키가이샤 기분 장애 치료용 카르보스티릴 유도체 및 세로토닌 재흡수억제제
AR042806A1 (es) 2002-12-27 2005-07-06 Otsuka Pharma Co Ltd Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo
FR2851163B1 (fr) * 2003-02-14 2007-04-27 Utilisation de l'enantiomere dextrogyre du milnacipran pour la preparation d'un medicament
KR20060009938A (ko) * 2003-05-16 2006-02-01 화이자 프로덕츠 인코포레이티드 양극성 장애 및 연관된 증상의 치료
EP2601953A1 (en) * 2003-05-23 2013-06-12 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives and mood stabilizers for treating mood disorders
EP1713486A4 (en) * 2003-12-02 2009-04-29 Sheldon Leslie James COMBINED THERAPY FOR THE TREATMENT OF DEMENTIA, DEPRESSION AND APATHY
JP2007513896A (ja) * 2003-12-15 2007-05-31 ハー・ルンドベック・アクチエゼルスカベット セロトニン再取り込み阻害剤およびヒスタミン３受容体アンタゴニスト、インバースアゴニストまたはパーシャルアゴニストの併用
WO2005102366A2 (en) * 2004-04-19 2005-11-03 Philip Maxwell Satow Lithium combinations, and uses related thereto
WO2005120523A1 (en) * 2004-06-04 2005-12-22 Mood Management Sciences, Llc Methods and compositions for treating mood disorder
MY147767A (en) 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
DK2453024T3 (en) 2004-06-21 2018-02-12 Univ Leland Stanford Junior Genes and conduits that are differentially expressed in bipolar disorder and / or major depressive disorder
AU2006315562C1 (en) 2005-11-12 2013-10-03 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating depression using NCAM peptide mimetics
US8691867B2 (en) 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
WO2007137167A2 (en) 2006-05-19 2007-11-29 Janssen Pharmaceutica N.V. Co-therapy for the treatment of epilepsy
US20080199866A1 (en) * 2006-10-10 2008-08-21 The Board Of Trustees Of The Leland Stanford Junior University Snp detection and other methods for characterizing and treating bipolar disorder and other ailments
GB0814466D0 (en) * 2008-08-07 2008-09-10 Rosemont Pharmaceuticals Ltd Sertraline composition
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
CN108938645A (zh) * 2018-08-24 2018-12-07 山西医科大学第医院 一种抗精神病药物组合物
CN108926569A (zh) * 2018-08-24 2018-12-04 山西医科大学第医院 一种非典型抗精神病药物组合物
CN109464436A (zh) * 2019-01-10 2019-03-15 高智玉 西酞普兰或艾司西酞普兰分别和喹硫平联合在制备治疗精神障碍类疾病的复方制剂中的应用
CN110151718A (zh) * 2019-06-13 2019-08-23 厦门医学院 一种奥氮平口腔崩解片及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8072691A (en) * 1990-06-28 1992-01-23 Beecham Group Plc Pharmaceutical preparations
HUP9903679A3 (en) * 1996-03-11 2001-10-29 Lilly Co Eli Use of olanzapine for the preparation of pharmaceutical compositions treating bipolar disorder
NZ332039A (en) * 1996-03-25 2000-06-23 Lilly Co Eli Method for treating pain using olanzapine and NSAIDs
ZA977967B (en) * 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses

Also Published As

Publication number Publication date
CN1302207A (zh) 2001-07-04
IL139591A0 (en) 2002-02-10
SK17492000A3 (sk) 2002-04-04
EA003611B1 (ru) 2003-06-26
ZA200006817B (en) 2002-02-21
KR20010043731A (ko) 2001-05-25
AU756468B2 (en) 2003-01-16
JP2002516864A (ja) 2002-06-11
EP0966967A3 (en) 2000-05-31
PL344304A1 (en) 2001-10-22
HUP0102511A2 (hu) 2001-11-28
AU4008899A (en) 1999-12-20
CA2332408A1 (en) 1999-12-09
NO20005884D0 (no) 2000-11-21
CZ20004280A3 (cs) 2001-09-12
NO20005884L (no) 2001-01-24
EP0966967A2 (en) 1999-12-29
WO1999062522A1 (en) 1999-12-09
EA200001244A1 (ru) 2001-06-25
NZ507981A (en) 2003-10-31
TR200003525T2 (tr) 2001-04-20
HRP20000798A2 (en) 2001-10-31

Similar Documents

Publication Publication Date Title
BR9911068A (pt) Terapia combinada para tratamento de distúrbios bipolares
FI963294A0 (fi) Naftyyliamidit keskushermostoaineina
BRPI0414794A (pt) oxadiazolidinadionas substituìdas
NO20042964L (no) Spiroazasykliske forbindelser som monoaminreseptormodulatorer
DK1955700T3 (da) Terapeutisk behandling af androgenreceptor-betingede lidelser
BR9917038A (pt) Composto, composição farmacêutica, método de modulação da atividade receptora de quimocinas, método de tratamento ou prevenção de doenças inflamatórias, método de tratamento ou prevenção de asma e método de tratamento ou prevenção de disfunções inflamatórias
AU1850801A (en) The combination of a serotonin reuptake inhibitor and irindalone
ATE380029T1 (de) Prodrugs von gaba-analoga, zusammensetzungen und ihre verwendungszwecke
BR0109211A (pt) Compostos com atividade 5-ht1a úteis para o tratamento de distúrbios da retina externa
BRPI0415409A (pt) uso de efetuadores de ciclases de glutaminila e glutamato
BR0208373A (pt) Inibidores da tirosina cinase
MY129189A (en) Prostaglandin agonists and their use to treat bone disorders
BR0011172A (pt) Derivados do 4,5-diaril-3(2h)-furanona como inibidores de cliclooxigenase-2
BR9911049A (pt) Terapia combinada para tratamento de depressão resistente
ATE357438T1 (de) 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems
BR0315437A (pt) Composição para o tratamento dos cabelos, usos da mesma e método para o tratamento dos cabelos
DE60141636D1 (de) Phospholipidderivate von valproinsäure und ihre kombinationen
BRPI0507250A (pt) combinações para tratar desordens do snc
BRPI0414049A (pt) compostos e composições como inibidores de proteìna cinase
BR9914848A (pt) Composição e processo para o tratamento de distúrbios da retina externa
WO2004047727A3 (en) Compositions and methods for diagnosing and treating mood disorders
AU2002347984A1 (en) Use of norepinephrine reuptake inhibitors for the treatment of tic disorders
ATE482217T1 (de) Dithiolopyrrolon-derivate zur behandlung von proliferativen störungen
ATE423772T1 (de) Morpholinderivate als inhibitoren der wiederaufnahme von norepinephrin
ATE409469T1 (de) Verwendung von 2,2,3,3, tetramethylcyclopropane carbonsäure derivaten zur behandlung von psychiatrischen störungen

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1911 DE 21/08/2007.